Garibotto, Valentina http://orcid.org/0000-0003-2422-698X
Albert, Nathalie L.
Barthel, Henryk
van Berckel, Bart
Boellaard, Ronald
Brendel, Matthias
Cecchin, Diego
Ekmekcioglu, Ozgul
van de Giessen, Elsmarieke
Guedj, Eric
Lammerstma, Adriaan A.
Semah, Franck
Traub-Weidinger, Tatjana
Van Weehaeghe, Donatienne
Morbelli, Silvia
,
Article History
First Online: 17 July 2021
Declarations
:
: Institutional Review Board approval was not required because the paper is an Editorial.
: Not applicable.
: Not applicable.
: Valentina Garibotto reports grants from the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355) the Schmidheiny foundation and the Velux foundation (project 1123). Valentina Garibotto received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck.Bart van Berckel received research support from ZON-MW, AVID radiopharmaceuticals, CTMM, and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria.Henryk Barthel received speaker honoraria from Novartis/AAA.Matthias Brendel reports grants by the German Research Foundation (projects BR4580/1–1; EXC 2145 SyNergy – ID 390857198), LMU Munich (project 980), and the Alzheimer Forschung Initiative e.V. (project 19063p). Matthias Brendel received speaker honoraria from GE healthcare, Roche, and Life Molecular Imaging, and is an advisor of Life Molecular Imaging.Diego Cecchin received free doses for CE approved amyloid PET acquisitions form Life Molecular Imaging and from GE Healthcare in 2019–2021.Eric Guedj received financial support from Life Molecular Imaging for an amyloid PET project in 2017; and from GE Healthcare, Curium, and AAA/Novartis on topics unrelated to this article.Silvia Morbelli received speaker honoraria from GE healthcare.All other authors have no conflicts of interest to disclose.
Free to read: This content has been made available to all.